10.37
+0.52(+5.28%)
Currency In USD
| Previous Close | 9.85 |
| Open | 10.28 |
| Day High | 10.65 |
| Day Low | 9.89 |
| 52-Week High | 10.65 |
| 52-Week Low | 4.63 |
| Volume | 226,171 |
| Average Volume | 115,063 |
| Market Cap | 47.31M |
| PE | -13.83 |
| EPS | -0.75 |
| Moving Average 50 Days | 7.86 |
| Moving Average 200 Days | 6.47 |
| Change | 0.52 |
If you invested $1000 in Tenax Therapeutics, Inc. (TENX) 10 years ago, it would be worth $0.1 as of December 14, 2025 at a share price of $10.37. Whereas If you bought $1000 worth of Tenax Therapeutics, Inc. (TENX) shares 5 years ago, it would be worth $5.95 as of December 14, 2025 at a share price of $10.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenax Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 03, 2025 12:00 PM GMT
CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary thera